Physician profile
John Peterson
NPI 1417957234
$9,273.25
in general payments reported to CMS, 2019-2025
85 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $2,292 · 2021: $2,214 · 2022: $876 · 2023: $921 · 2024: $622 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.98 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $807.27 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $558.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $529.78 | 2019-2024 | Keytruda, Lenvima |
| Janssen Biotech, INC. | $521.41 | 2019-2025 | Rybrevant |
| Amgen INC. | $472.15 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Pfizer INC. | $437.93 | 2019-2024 | |
| Genentech USA, INC. | $431.75 | 2019-2023 | Venclexta, Tecentriq, Gavreto |
| Daiichi Sankyo INC. | $405.29 | 2019-2023 | Enhertu |
| Incyte Corporation | $335.23 | 2019-2024 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $308.45 | 2019-2025 | Fruzaqla, Ninlaro |
| Genzyme Corporation | $268.74 | 2019-2024 | |
| Eisai INC. | $260.21 | 2019-2025 | |
| Seagen INC. | $220.22 | 2019-2023 | Tukysa, Padcev |
| Exelixis INC. | $216.04 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $143.86 | 2019 |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.